INTEGRATED BIOPHARMA INC Annual Deferred Federal Income Tax Expense (Benefit) in USD from 2023 to 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Integrated Biopharma Inc quarterly/annual Deferred Federal Income Tax Expense (Benefit) history and growth rate from 2023 to 2024.
  • Integrated Biopharma Inc Deferred Federal Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $190K, a 3067% increase year-over-year.
  • Integrated Biopharma Inc Deferred Federal Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $308K, a 211% increase year-over-year.
  • Integrated Biopharma Inc annual Deferred Federal Income Tax Expense (Benefit) for 2024 was $124K, a 125% increase from 2023.
Deferred Federal Income Tax Expense (Benefit), Trailing 12 Months (USD)
Deferred Federal Income Tax Expense (Benefit), Annual (USD)
Deferred Federal Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $124K +$69K +125% Jul 1, 2023 Jun 30, 2024 10-K 2024-09-20
2023 $55K Jul 1, 2022 Jun 30, 2023 10-K 2024-09-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.